A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood

Volumn 138, Issue 14, 2021, Pages 1258-1268

  Østergaard, Henrik ^a   Lund, Jacob ^a   Greisen, Per J ^a   Kjellev, Stine ^a   Henriksen, Anette ^a   Lorenzen, Nikolai ^a   Johansson, Eva ^a   Røder, Gustav ^a   Rasch, Morten G ^a   Johnsen, Laust B ^a   Egebjerg, Thomas ^a   Lund, Søren ^a   Rahbek Nielsen, Henrik ^a   Gandhi, Prafull S ^a   Lamberth, Kasper ^a   Loftager, Mette ^a   Andersen, Lisbeth M ^a   Bonde, Amalie C ^a   Stavenuiter, Fabian ^a   Madsen, Daniel E ^a   Li, Xun ^b   Holm, Thomas L ^a   Ley, Carsten D ^a   Thygesen, Peter ^a   Zhu, Haisun ^b   Zhou, Rong ^b   Thorn, Karina ^a   Yang, Zhiru ^b   Hermit, Mette B ^a   Bjelke, Jais R ^a   Hansen, Bjarne G ^a   Hilden, Ida ^a   more..

^a NOVO NORDISK A S   (Denmark)

^b SIBS Novo Nordisk Translational Research Centre for PreDiabetes   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY MIM8; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; EMICIZUMAB; THROMBIN; UNCLASSIFIED DRUG;

ABSORPTION HALF-LIFE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE SEVERITY; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; EC50; FEMALE; HEMOPHILIA A; HEMOSTASIS; HUMAN; MACACA FASCICULARIS; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PHOSPHOLIPID MEMBRANE; PRECLINICAL STUDY; PROTEIN DEGRADATION; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TAIL VEIN; THROMBIN TIME; ANIMAL; BLEEDING; C57BL MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; FACTOR IXA; FACTOR VIIIA; FACTOR X; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MICE, INBRED C57BL;

EID: 85116702227     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood.2020010331     Document Type: Article

References (41)

1. Young, G, Mahlangu, JN, Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 22 (2016), 25–30 suppl 5.
2. Gouw, SC, van der Bom, JG, Marijke van den Berg, H, Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 109:11 (2007), 4648–4654.
3. Meeks, SL, Batsuli, G, Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016 (2016), 657–662.
4. Kitazawa, T, Igawa, T, Sampei, Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 18:10 (2012), 1570–1574.
5. Oldenburg, J, Mahlangu, JN, Kim, B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 377:9 (2017), 809–818.
6. Mahlangu, J, Oldenburg, J, Paz-Priel, I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 379:9 (2018), 811–822.
7. Lenting, PJ, Denis, CV, Christophe, OD, Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood. 130:23 (2017), 2463–2468.
8. Sampei, Z, Igawa, T, Soeda, T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One., 8(2), 2013, e57479.
9. Nesheim, M, Pittman, DD, Giles, AR, et al. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem. 266:27 (1991), 17815–17820.
10. Saenko, EL, Scandella, D, A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem. 270:23 (1995), 13826–13833.
11. Lenting, PJ, Donath, MJ, van Mourik, JA, Mertens, K, Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem. 269:10 (1994), 7150–7155.
12. Spaargaren, J, Giesen, PL, Janssen, MP, Voorberg, J, Willems, GM, van Mourik, JA, Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry. Biochem J. 310:pt 2 (1995), 539–545.
13. Mertens, K, Cupers, R, Van Wijngaarden, A, Bertina, RM, Binding of human blood-coagulation factors IXa and X to phospholipid membranes. Biochem J. 223:3 (1984), 599–605.
14. Fay, PJ, Koshibu, K, The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 273:30 (1998), 19049–19054.
15. Basavaraj, MG, Krishnaswamy, S, Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex. J Biol Chem. 295:45 (2020), 15198–15207.
16. Mutucumarana, VP, Duffy, EJ, Lollar, P, Johnson, AE, The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study. J Biol Chem. 267:24 (1992), 17012–17021.
17. Kolkman, JA, Mertens, K, Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII. Biochemistry. 39:25 (2000), 7398–7405.
18. Zögg, T, Brandstetter, H, Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa. Structure. 17:12 (2009), 1669–1678.
19. Freato, N, Ebberink, EHTM, van Galen, J, et al. Factor VIII-driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry. Blood. 136:23 (2020), 2703–2714.
20. Fay, PJ, Activation of factor VIII and mechanisms of cofactor action. Blood Rev. 18:1 (2004), 1–15.
21. Kitazawa, T, Esaki, K, Tachibana, T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 117:7 (2017), 1348–1357.
22. Labrijn, AF, Meesters, JI, de Goeij, BE, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A. 110:13 (2013), 5145–5150.
23. Labrijn, AF, Meesters, JI, Priem, P, et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc. 9:10 (2014), 2450–2463.
24. Johansen, PB, Tranholm, M, Haaning, J, Knudsen, T, Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice—characterization of two novel FVIII molecules. Haemophilia. 22:4 (2016), 625–631.
25. Lee, EC, Liang, Q, Ali, H, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol. 32:4 (2014), 356–363.
26. Douglass, EF Jr, Miller, CJ, Sparer, G, Shapiro, H, Spiegel, DA, A comprehensive mathematical model for three-body binding equilibria. J Am Chem Soc. 135:16 (2013), 6092–6099.
27. Merchant, M, Ma, X, Maun, HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 110:32 (2013), E2987–E2996.
28. Wu, J, Schultz, JS, Weldon, CL, et al. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy. Protein Eng Des Sel. 28:10 (2015), 403–414.
29. Banner, DW, D'Arcy, A, Chène, C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 380:6569 (1996), 41–46.
30. Johnson, DJ, Langdown, J, Huntington, JA, Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex. Proc Natl Acad Sci U S A. 107:2 (2010), 645–650.
31. Johnson, DJ, Li, W, Adams, TE, Huntington, JA, Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J. 25:9 (2006), 2029–2037.
32. Pomowski, A, Ustok, FI, Huntington, JA, Homology model of human prothrombinase based on the crystal structure of Pseutarin C. Biol Chem. 395:10 (2014), 1233–1241.
33. Mathur, A, Bajaj, SP, Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. J Biol Chem. 274:26 (1999), 18477–18486.
34. Bajaj, SP, Schmidt, AE, Mathur, A, et al. Factor IXa:factor VIIIa interaction. helix 330-338 of factor IXa interacts with residues 558-565 and spatially adjacent regions of the a2 subunit of factor VIIIa. J Biol Chem. 276:19 (2001), 16302–16309.
35. Nelsestuen, GL, Kisiel, W, Di Scipio, RG, Interaction of vitamin K dependent proteins with membranes. Biochemistry. 17:11 (1978), 2134–2138.
36. Tavoosi, N, Smith, SA, Davis-Harrison, RL, Morrissey, JH, Factor VII and protein C are phosphatidic acid-binding proteins. Biochemistry. 52:33 (2013), 5545–5552.
37. Kaufman, EN, Jain, RK, Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res. 52:15 (1992), 4157–4167.
38. Niewoehner, J, Bohrmann, B, Collin, L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 81:1 (2014), 49–60.
39. Kristensen, LH, Olsen, OH, Blouse, GE, Brandstetter, H, Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site. Biochem J. 473:15 (2016), 2395–2411.
40. Scheiflinger, F, Dockal, M, Rosing, J, Kerschbaumer, RJ, Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies. J Thromb Haemost. 6:2 (2008), 315–322.
41. Ferrière, S, Peyron, I, Christophe, OD, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 136:6 (2020), 740–748.